Form 4: Indivior Director Barbara Ryan Receives RSU Grant

Indivior Pharmaceuticals, Inc. Director Barbara Ryan was granted 3,722 Restricted Stock Units, vesting before the next annual meeting.

Summary

• Director Barbara Ryan of Indivior Pharmaceuticals, Inc. [INDV] received a grant of 3,722 Restricted Stock Units (RSUs) on January 26, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date.
• Vesting is contingent upon Ms. Ryan's continued service to the Issuer on the vesting date.
• Following this transaction, Ms. Ryan's beneficial ownership increased to 5,685 shares of common stock.

Sentiment

Score: 7

Explanation: A routine equity grant to a director, which is generally positive for aligning interests, but not a major market-moving event that would significantly alter the company's fundamental outlook.

Positives

• Grant of 3,722 Restricted Stock Units (RSUs) to Director Barbara Ryan, aligning her interests with shareholders.
• Increased beneficial ownership for Director Barbara Ryan to 5,685 shares, demonstrating continued commitment to the company.

Risks

• The vesting of the 3,722 Restricted Stock Units is subject to the reporting person's continued service to the Issuer on the vesting date.

Future Outlook

The vesting of the granted Restricted Stock Units is tied to the director's continued service until the day preceding the first annual stockholders' meeting following the grant date, indicating an expectation of ongoing commitment and alignment with long-term company performance.

Industry Context

This is a routine equity compensation event for a director, common across publicly traded companies to align executive and director incentives with long-term shareholder value. It does not reflect broader industry trends or competitive positioning directly within the pharmaceutical sector.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of director compensation is a standard practice in the pharmaceutical industry and across public companies.
• This method aligns director interests with shareholder value by tying compensation to future stock performance and continued service, similar to practices at companies like Pfizer, Johnson & Johnson, or Merck, which frequently use equity awards for their non-employee directors.

Stakeholder Impact

• Shareholders: The grant of RSUs to Director Barbara Ryan further aligns her financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• The granted Restricted Stock Units are scheduled to vest on the day immediately preceding the first annual meeting of the Issuer's stockholders following the grant date, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice designed to align management and director interests with shareholders. It does not provide new information that would fundamentally alter the investment thesis for Indivior Pharmaceuticals, Inc. Therefore, a 'hold' recommendation is appropriate as this event alone is not a catalyst for a 'buy' or 'sell' decision.

Keywords

Indivior Pharmaceuticals, INDV, Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Barbara Ryan